Literature DB >> 22623277

Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research.

Anna Asplund1, Per-Henrik D Edqvist, Jochen M Schwenk, Fredrik Pontén.   

Abstract

In this review, we present an update on the progress of the Human Protein Atlas, with an emphasis on strategies for validating immunohistochemistry-based protein expression patterns and on the possibilities to extend the map of protein expression patterns for cancer research projects. The objectives underlying the Human Protein Atlas include (i) the generation of validated antibodies toward a major isoform of all proteins encoded by the human genome, (ii) creating an information database of protein expression patterns in normal human tissues, in cells, and in cancer, and (iii) utilizing generated antibodies and protein expression data as tools to identify clinically useful biomarkers. The success of such an effort is dependent on the validity of antibodies as specific binders of intended targets in applications used to map protein expression patterns. The development of strategies to support specific target binding is crucial and remains a challenge as a large fraction of proteins encoded by the human genome is poorly characterized, including the approximately one-third of all proteins lacking evidence of existence. Conceivable methods for validation include the use of paired antibodies, i.e. two independent antibodies targeting different and nonoverlapping epitopes on the same protein as well as comparative analysis of mRNA expression patterns with corresponding proteins.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623277     DOI: 10.1002/pmic.201100504

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  101 in total

1.  Construction of a Ferroptosis-Related Gene Signature for Head and Neck Squamous Cell Carcinoma Prognosis Prediction.

Authors:  Qun Li; Yangli Jin; Zhisen Shen; Huigao Liu; Yi Shen; Zhenhua Wu
Journal:  Int J Gen Med       Date:  2021-12-21

2.  CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients.

Authors:  Dan Wang; Yanhong Zhou; Li Hua; Jiaxiang Li; Ni Zhu; Yifei Liu
Journal:  Int J Gen Med       Date:  2022-02-27

3.  Prospective role and immunotherapeutic targets of sideroflexin protein family in lung adenocarcinoma: evidence from bioinformatics validation.

Authors:  Huy Hoang Dang; Hoang Dang Khoa Ta; Truc T T Nguyen; Gangga Anuraga; Chih-Yang Wang; Kuen-Haur Lee; Nguyen Quoc Khanh Le
Journal:  Funct Integr Genomics       Date:  2022-07-19       Impact factor: 3.674

4.  [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].

Authors:  L Shang; W Jiang; J Zhang; W Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

5.  Comprehensive Analysis of the Expression and Prognostic Value of LMAN2 in HER2+ Breast Cancer.

Authors:  Di Zhang; Liping Ye; Shuang Hu; Qingqing Zhu; Chenxi Li; Chengming Zhu
Journal:  J Immunol Res       Date:  2022-06-06       Impact factor: 4.493

6.  Combining docking site and phosphosite predictions to find new substrates: identification of smoothelin-like-2 (SMTNL2) as a c-Jun N-terminal kinase (JNK) substrate.

Authors:  Elizabeth A Gordon; Thomas C Whisenant; Michael Zeller; Robyn M Kaake; William M Gordon; Pascal Krotee; Vishal Patel; Lan Huang; Pierre Baldi; Lee Bardwell
Journal:  Cell Signal       Date:  2013-08-24       Impact factor: 4.315

7.  Allograft Inflammatory Factor-1 Links T-Cell Activation, Interferon Response, and Macrophage Activation in Chronic Kawasaki Disease Arteritis.

Authors:  Anne H Rowley; Susan C Baker; Kwang-Youn A Kim; Stanford T Shulman; Amy Yang; David Arrollo; Matthew DeBerge; Shuling Han; Nicholas E S Sibinga; Adam J Pink; Edward B Thorp
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

8.  Comprehensive Analysis of Expression and Prognostic Value of GATAs in Lung Cancer.

Authors:  Chengwu Gong; Yun Fan; Xueliang Zhou; Songqing Lai; Lijun Wang; Jichun Liu
Journal:  J Cancer       Date:  2021-05-05       Impact factor: 4.207

9.  ALKBH1-8 and FTO: Potential Therapeutic Targets and Prognostic Biomarkers in Lung Adenocarcinoma Pathogenesis.

Authors:  Geting Wu; Yuanliang Yan; Yuan Cai; Bi Peng; Juanni Li; Jinzhou Huang; Zhijie Xu; Jianhua Zhou
Journal:  Front Cell Dev Biol       Date:  2021-06-03

10.  Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis.

Authors:  Xinyi Lei; Miao Zhang; Bingsheng Guan; Qiang Chen; Zhiyong Dong; Cunchuan Wang
Journal:  Hum Genomics       Date:  2021-06-29       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.